We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
Read MoreHide Full Article
Key Takeaways
HOLX pulled the HIV testing business in Africa from its 2025 forecast after USAID halted funding support.
Tariffs from China and Costa Rica are set to increase HOLX's inventory costs by up to $25M per quarter.
Hologic's Diagnostics momentum is driven by strong BV/CV test demand and Panther utilization growth.
Marlborough, MA-based Hologic (HOLX - Free Report) is navigating a shifting geopolitical landscape in each of its core businesses. In a conservative move, the company’s fiscal 2025 sales outlook now excludes the HIV testing business in Africa, which used to generate $50 million in revenues annually, following the halt in USAID funding. Hologic also cut its revenue forecast for China to nearly $50 million for the year due to heightened tariff pressure, growing anti-American sentiment and strong local competition for its cytology products.
Compounding this, tariffs related to manufacturing activities in Costa Rica and China are projected to raise quarterly inventory acquisition costs by nearly $20 million to $25 million, straining its profitability.
Still, the company remains confident in delivering solid financial results. Its cost-effective infectious disease and cancer tests support early detection and help reduce the overall healthcare costs, putting Hologic in a favorable spot in this macro environment. The Molecular diagnostics business is expected to remain a standout due to the strong demand for the BV/CV vaginitis assay and Biotheranostics’ Breast Cancer Index test. Further, the Panther platform’s existing installed base, growing utilization and menu are likely to continue to fuel the strong momentum in the Diagnostics segment.
The company’s Breast Health products offer a strong foundation. However, the service business — which grew 12% year over year in the fiscal 2025 second quarter — is relatively larger and growing faster than capital sales. Recent actions such as reorganizing the sales team and structure and enhancing the processes are already yielding favorable results for Hologic.
How Are Hologic’s Peers Holding Up?
Despite a cautious customer spending environment and evolving global trade dynamics, QIAGEN (QGEN - Free Report) has shown resilience. 2025 started on a solid note for the sample-to-solutions provider, with both first-quarter sales and adjusted EPS surpassing its outlook. QIAGEN reaffirmed approximately 4% constant exchange rate (CER) annual growth in its core portfolio. Meanwhile, QIAGEN’s 8% forecasted CER growth for the bottom line is supported by operational margin expansion while accounting for the current tariff environment.
Medtronic (MDT - Free Report) ended fiscal 2025 on a high note, supported by its growth drivers. For fiscal 2026, it projects a net tariff impact of approximately $200 million to $350 million on its cost of goods sold. Excluding the impact of tariffs, Medtronic expects approximately 4% EPS growth for the year. While underlying business fundamentals remain strong, Medtronic is actively working to overcome external factors while promising to return to high single-digit EPS growth in fiscal 2027.
HOLX Stock Price Performance
Over the past year, Hologic shares have dropped 10.1% compared with the industry’s decline of 13.9%.
Image Source: Zacks Investment Research
Hologic’s Valuation
From a valuation standpoint, HOLX trades at a forward 12-month price-to-sales (P/S) of 3.44X, lower than its median of 3.99X, as well as the 4.11X industry average of 4.11X. It carries a Value Score of B.
Image Source: Zacks Investment Research
HOLX Stock Consensus Estimate Trend
Take a look at how the Zacks Consensus Estimate for HOLX’s earnings has been revised over the past 90 days.
Image: Bigstock
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
Key Takeaways
Marlborough, MA-based Hologic (HOLX - Free Report) is navigating a shifting geopolitical landscape in each of its core businesses. In a conservative move, the company’s fiscal 2025 sales outlook now excludes the HIV testing business in Africa, which used to generate $50 million in revenues annually, following the halt in USAID funding. Hologic also cut its revenue forecast for China to nearly $50 million for the year due to heightened tariff pressure, growing anti-American sentiment and strong local competition for its cytology products.
Compounding this, tariffs related to manufacturing activities in Costa Rica and China are projected to raise quarterly inventory acquisition costs by nearly $20 million to $25 million, straining its profitability.
Still, the company remains confident in delivering solid financial results. Its cost-effective infectious disease and cancer tests support early detection and help reduce the overall healthcare costs, putting Hologic in a favorable spot in this macro environment. The Molecular diagnostics business is expected to remain a standout due to the strong demand for the BV/CV vaginitis assay and Biotheranostics’ Breast Cancer Index test. Further, the Panther platform’s existing installed base, growing utilization and menu are likely to continue to fuel the strong momentum in the Diagnostics segment.
The company’s Breast Health products offer a strong foundation. However, the service business — which grew 12% year over year in the fiscal 2025 second quarter — is relatively larger and growing faster than capital sales. Recent actions such as reorganizing the sales team and structure and enhancing the processes are already yielding favorable results for Hologic.
How Are Hologic’s Peers Holding Up?
Despite a cautious customer spending environment and evolving global trade dynamics, QIAGEN (QGEN - Free Report) has shown resilience. 2025 started on a solid note for the sample-to-solutions provider, with both first-quarter sales and adjusted EPS surpassing its outlook. QIAGEN reaffirmed approximately 4% constant exchange rate (CER) annual growth in its core portfolio. Meanwhile, QIAGEN’s 8% forecasted CER growth for the bottom line is supported by operational margin expansion while accounting for the current tariff environment.
Medtronic (MDT - Free Report) ended fiscal 2025 on a high note, supported by its growth drivers. For fiscal 2026, it projects a net tariff impact of approximately $200 million to $350 million on its cost of goods sold. Excluding the impact of tariffs, Medtronic expects approximately 4% EPS growth for the year. While underlying business fundamentals remain strong, Medtronic is actively working to overcome external factors while promising to return to high single-digit EPS growth in fiscal 2027.
HOLX Stock Price Performance
Over the past year, Hologic shares have dropped 10.1% compared with the industry’s decline of 13.9%.
Image Source: Zacks Investment Research
Hologic’s Valuation
From a valuation standpoint, HOLX trades at a forward 12-month price-to-sales (P/S) of 3.44X, lower than its median of 3.99X, as well as the 4.11X industry average of 4.11X. It carries a Value Score of B.
Image Source: Zacks Investment Research
HOLX Stock Consensus Estimate Trend
Take a look at how the Zacks Consensus Estimate for HOLX’s earnings has been revised over the past 90 days.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.